UCV mRNA Vaccine2022-06-10T06:16:16+00:00

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 pathogen.

About UCV mRNA Vaccine

From an epidemiological standpoint, there have been over 500 million cases worldwide. Most people infected with the virus experience mild to moderate respiratory illness and recover without requiring special treatment. However, some become seriously ill and require medical attention. Older people and those with underlying medical conditions such as cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness. Anyone can get sick with COVID-19 and become seriously ill or die at any age. It is very contagious and has quickly spread around the world. COVID-19 most often causes respiratory symptoms that can feel much like a cold, a flu, or pneumonia. COVID-19 may attack more than your lungs and respiratory system. Other parts of your body may also be affected by the disease. Most people with COVID-19 have mild symptoms, but some people become severely ill. Some people including those with minor or no symptoms may suffer from post-COVID conditions — or “long COVID”. Older adults and people who have certain underlying medical conditions are at increased risk of severe illness from COVID-19. Hundreds of thousands of people have died from COVID-19 in the United States. Vaccines against COVID-19 are safe and effective. Vaccines teach our immune system to fight the virus that causes COVID-19.

One of the best ways to prevent the spread of the disease is with safe and effective vaccines.

The goal of the Universal Coronavirus mRNA Vaccine (UCV-mRNA) in development by Normax with UKvax Factory and the mRNA UCV Consortium is to help solve the urgent global need for a one-time COVID-19 booster to save lives and help to end the COVID-19 pandemic and to support innovation for future pandemic preparedness.

Universal Coronavirus mRNA Vaccine Pipeline

DEVELOPMENT

PRECLINCAL

PHASE 1

PHASE 2

PHASE 3

INDICATION
Universal Coronavirus mRNA Vaccine (UCV-mRNA)

GLOBAL PUBLIC HEALTH IMPACT
Prophylactic mRNA Vaccine. Therapeutic mRNA Vaccine (long-covid)

PARTNERS / SUPPORTERS
mRNA UCV Consortium

COMMERCIAL
Normax

LICENSING
Vaxcomm

UCV mRNA Vaccine Pipeline

DEVELOPMENT

INDICATION
Universal Coronavirus mRNA Vaccine

TECHNOLOGY
Prophylactic mRNA Vaccine. Therapeutic mRNA Vaccine (long-covid)

PARTNERS / SUPPORTERS
mRNA UCV Consortium

COMMERCIAL
Normax

LICENSING
Vaxcomm

Pricing

Our goal is to be able to mass-produce a vaccine that is both highly efficient and affordable for the general public, that we will be able to distribute at the cost of only $4 per dose.

The average cost of an ER visit for mild to moderate COVID that needs medical intervention is ~$2,000. The average cost per day in a hospital is approximately $2600. The average ICU stay is $8700 per day.

Source: KFF

Go to Top